Furthermore, we also analyzed the prognosis of the 156 liver cancer patients with high and low expression of NCOA3/TERT/SP1 in the clinic date sets of the GEO database (GSE10143) and found the patients with high expression with NCOA3, SP1, or TERT have a poor prognosis comparison the HCC patients with low expression of this gene (Fig. S2E). This evidence concerns the gene NCOA3 and liver cancer.